President Trump Admitted to Walter Reed, Receives Experimental COVID Treatment
President Donald Trump will be admitted to Walter Reed Medical Center as a precautionary measure today (October 2) after testing positive for COVID-19.
Per The Washington Post, USA Today and Fox News, President Trump will undergo various tests while at Walter Reed and will be admitted for a few days.
White House Press Secretary Kayleigh McEnany shared a statement from President Trump’s doctor, Dr. Sean P. Conley, that further details his condition and treatment.
“Following PCR-confirmation of the President’s diagnosis, as a precautionary measure he received a single 8 gram dose of Regeneron’s polyclonal antibody cocktail. He completed the infusion without incident,” read Dr. Conley’s statement. “In addition to the polyclonal antibodies, the President had been taking zinc, vitamin D, famotidine, melatonin and a daily aspirin.”
Dr. Conley added, “As of this afternoon, the President remains fatigued but in good spirits. He’s being evaluated by a team of experts, and together we’ll be making recommendations to the President and First Lady in regards to next best steps.”
“First Lady Melania Trump remains well with only a mild cough and headache, and the remainder fo the First Family are well and tested negative for SARS-CoV-2 today,” concluded the statement.
An update from President @realDonaldTrump's physician: pic.twitter.com/cTsXO4Df6b
— Kayleigh McEnany 45 Archived (@PressSec45) October 2, 2020
Regarding receiving Regeneron, Dr. Leonard S. Schleifer, Regeneron’s chief executive, told The New York Times, “All we can say is that they asked to be able to use it, and we were happy to oblige. When it’s the president of the United States, of course, that gets — obviously — gets our attention.”
President Trump’s medical staff “…reached out to the company for permission to use the drug, and that it was cleared with the Food and Drug Administration.” Dr. Schleifer added that the use of Regeneron is “decided on a case-by-case basis and he is not the first patient to granted permission to use the treatment this way” outside of its clinical trials.
